Search results for "Cancer."

showing 10 items of 11362 documents

MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma

2020

Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients' samples. The upregulation of miR-33b suppressed proliferatio…

0301 basic medicineHER2+Mama ExamenCancer ResearchmiRNA-33bCellular differentiationVimentinMYCmacromolecular substanceslcsh:RC254-28203 medical and health sciences0302 clinical medicinebreast cancerDownregulation and upregulationmicroRNAGene silencingEpithelial–mesenchymal transitionEZH2CàncerbiologyCell growthChemistryEZH2EMTlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisbiology.proteinCancer research
researchProduct

Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Revi…

2021

Simple Summary Serum antibodies against human papillomavirus 16 (HPV16) proteins are associated with HPV-driven oropharyngeal cancer (HPV-OPC). The HPV status of OPC cases is clinically relevant because patients with HPV-OPC show improved survival and treatment response compared to tobacco- or alcohol-induced OPC. In clinical settings, molecular HPV tumor status is usually determined by tissue-based methods detecting molecular markers, such as viral nucleic acids or p16 overexpression. Antibodies against HPV16 in peripheral blood were shown to be very accurate in determining the molecular HPV tumor status in multiple studies. In this work, we reviewed and summarized the available literature…

0301 basic medicineHPVCancer Researchmedicine.medical_specialtyoropharyngeal cancerserologyspecificityGastroenterologySerology03 medical and health sciences0302 clinical medicinesystematic reviewAntigenInternal medicineparasitic diseasesmedicineantibodiesRC254-282biologybusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensvirus diseasesCancersensitivitymedicine.diseaseConfidence intervalmeta-analysis030104 developmental biologyOncology030220 oncology & carcinogenesisMeta-analysisbiology.proteinBiomarker (medicine)ImmunohistochemistryAntibodybusinessCancers
researchProduct

Molecular bases of the poor response of liver cancer to chemotherapy

2018

Summary A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting fo…

0301 basic medicineHepatoblastomaCarcinoma HepatocellularGenetic enhancementmedicine.medical_treatmentCholangiocarcinoma03 medical and health sciences0302 clinical medicineHumansMedicinecholangiocarcinoma; hepatoblastoma; hepatocellular carcinoma; multidrug resistance; targeted therapies; hepatology; gastroenterologyChemotherapyHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseasePhenotypeResistome030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCancer cellCancer researchbusinessLiver cancerClinics and Research in Hepatology and Gastroenterology
researchProduct

Novel deletion in 11p15.5 imprinting center region 1 in a patient with Beckwith-Wiedemann syndrome provides insight into distal enhancer regulation a…

2016

Background Beckwith–Wiedemann syndrome (BWS) is an early-onset overgrowth disorder with a high risk for embryonal tumors. It is mainly caused by dysregulation of imprinted genes on chromosome 11p15.5; however, the driving forces in the development of tumors are not fully understood. Procedure We report on a female patient presenting with macrosomia, macroglossia, organomegaly and extensive bilateral nephroblastomatosis. Adjuvant chemotherapy was initiated; however, the patient developed hepatoblastoma and Wilms tumor at 5 and 12 months of age, respectively. Subsequent radiofrequency ablation of the liver tumor and partial nephrectomy followed by consolidation therapy achieved complete remis…

0301 basic medicineHepatoblastomaPathologymedicine.medical_specialtyBeckwith-Wiedemann SyndromeBeckwith–Wiedemann syndrome030105 genetics & hereditymedicine.disease_cause03 medical and health sciencesGenomic ImprintingInsulin-Like Growth Factor IIMacroglossiaMedicineHumansImprinting (psychology)NephroblastomatosisSequence Deletionbusiness.industryChromosomes Human Pair 11Infant NewbornWilms' tumorHematologyDNA Methylationmedicine.diseasePrognosis030104 developmental biologyCell Transformation NeoplasticPhenotypeOncologyPediatrics Perinatology and Child HealthCancer researchFemalemedicine.symptombusinessGenomic imprintingCarcinogenesisPediatric bloodcancer
researchProduct

Functional inhibition of Oct leads to HNF4α upregulation

2021

Organic cation transporters (human, OCT; mouse, Oct) are responsible for the intracellular uptake and detoxification of a broad spectrum of endogenous and exogenous substrates. The OCT1 gene SLC22A1 (human; mouse, Scl22a1) is transactivated by hepatocyte nuclear factor 4α (human, HNF4α; mouse, Hnf4α). HNF4α is a master regulator of hepatocyte differentiation and is frequently associated with hepatocellular carcinoma (HCC). In addition, the downregulation of HNF4α is associated with enhanced fibrogenesis. Our recent study revealed that hepatocarcinogenesis and fibrosis were enhanced with the loss of Oct3 (gene, Slc22a3). Notably, differences in Hnf4α expression, and in cholestasis and fibros…

0301 basic medicineHepatocyte differentiationCancer ResearchOncogeneChemistryArticlesGeneral Medicineorganic cation transportermedicine.diseaseMolecular biology03 medical and health sciencesHepatocyte nuclear factors030104 developmental biology0302 clinical medicineImmunology and Microbiology (miscellaneous)CholestasisDownregulation and upregulationApoptosisFibrosis030220 oncology & carcinogenesisGene expressionmedicineSLC22A3HNF4αSLC22A1Experimental and Therapeutic Medicine
researchProduct

Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas

2019

BACKGROUND & AIMS: Colorectal cancer is an epigenetically heterogeneous disease, however, the extent and spectrum of the CpG island methylator phenotype (CIMP) is not clear. METHODS: Genome-scale methylation and transcript expression were measured by DNA Methylation and RNA expression microarray in 216 unselected colorectal cancers, and findings were validated using The Cancer Genome Atlas 450K and RNA sequencing data. Mutations in epigenetic regulators were assessed using CIMP-subtyped Cancer Genome Atlas exomes. RESULTS: CIMP-high cancers dichotomized into CIMP-H1 and CIMP-H2 based on methylation profile. KRAS mutation was associated significantly with CIMP-H2 cancers, but not CIMP-H1 can…

0301 basic medicineHepatologyCpG Island Methylator PhenotypeColorectal cancerGastroenterologyMethylationBiologymedicine.disease_causemedicine.diseasedigestive system diseases3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicineDNA methylationCancer researchmedicinelcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyKRASEpigeneticslcsh:RC799-869neoplasmsGeneExome sequencingCellular and Molecular Gastroenterology and Hepatology
researchProduct

2019

Abstract Background Comprehensive transcriptomic analyses have shown that colorectal cancer (CRC) is heterogeneous and have led to the definition of molecular subtypes among which the stem-cell, mesenchymal-like group is associated with poor prognosis. The molecular pathways orchestrating the emergence of this subtype are incompletely understood. In line with the contribution of the cellular prion protein PrPC to stemness, we hypothesize that deregulation of this protein could lead to a stem-cell, mesenchymal-like phenotype in CRC. Methods We assessed the distribution of the PrPC-encoding PRNP mRNA in two large CRC cohorts according to molecular classification and its association with patie…

0301 basic medicineHippo signaling pathwayColorectal canceranimal diseasesMesenchymal stem cellCancerGeneral MedicineBiologymedicine.diseasePhenotypeGeneral Biochemistry Genetics and Molecular Biologynervous system diseases3. Good healthPRNPTranscriptome03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesismental disordersCancer researchmedicineGeneEBioMedicine
researchProduct

A novel community driven software for functional enrichment analysis of extracellular vesicles data

2017

Bioinformatics tools are imperative for the in depth analysis of heterogeneous high-throughput data. Most of the software tools are developed by specific laboratories or groups or companies wherein they are designed to perform the required analysis for the group. However, such software tools may fail to capture "what the community needs in a tool". Here, we describe a novel community-driven approach to build a comprehensive functional enrichment analysis tool. Using the existing FunRich tool as a template, we invited researchers to request additional features and/or changes. Remarkably, with the enthusiastic participation of the community, we were able to implement 90% of the requested feat…

0301 basic medicineHistologyComputer scienceDownloadShort CommunicationCell- och molekylärbiologicomputer.software_genreExtracellular vesiclesArticleWorld Wide WebFunRich03 medical and health sciences0302 clinical medicineSoftwareRZSettore BIO/13 - Biologia ApplicataJournal ArticleMedicine and Health SciencesPlug-inlcsh:QH573-671Scientific disciplinesbusiness.industrylcsh:CytologySoftware developmentCell BiologybioinformaticsExtracellular vesiclesData scienceCANCERExtracellular vesicles; FunRich; bioinformaticsCell and molecular biology030104 developmental biology030220 oncology & carcinogenesisExtracellular vesicleAnalysis toolsbusinesscomputerCell and Molecular Biology
researchProduct

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

2020

Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelia…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyhalloysite nanotubesengineering.materialHalloysiteProdigiosin03 medical and health scienceschemistry.chemical_compoundcomet assaylcsh:TP248.13-248.65Cytotoxic T cellcancerOriginal Researchgenotoxic effectanti-cancer drugsbiologyChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologybiology.organism_classificationmalignant cellsComet assay030104 developmental biologyprodigiosinDrug deliveryToxicitySerratia marcescensdrug deliveryCancer researchengineering0210 nano-technologyDrug carrierBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Childhood cancer predisposition syndromes-A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatri…

2017

Heritable predisposition is an important cause of cancer in children and adolescents. Although a large number of cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more pediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. In a consensus meeting in the beginning of 2016, we convened experts in Human Genetics and Pediatric Hematology/Oncology to review the available data, to categorize the large amount of information, and to develop recommendations regarding when a cancer predisposition syndrome should be suspected in a young oncology patient. This review su…

0301 basic medicineHistoryMedizinGene Expression0302 clinical medicineNeoplasm Proteins/geneticsNeoplasmsChildGenetics (clinical)Societies Medicalddc:618HematologyJuvenile myelomonocytic leukemiaCancer predispositionSyndromeFocus Groups21st Century3. Good healthNeoplasm Proteins030220 oncology & carcinogenesisHematologic NeoplasmsGenetic Testing/methodsmedicine.medical_specialtyAdolescentGenetics MedicalGenetic CounselingHistory 21st CenturyMedical/history/instrumentation/methodsFamilial adenomatous polyposis03 medical and health sciencesInternal medicineGeneticsmedicineHumansFocus Groups/methodsGenetic Predisposition to DiseaseGenetic TestingIntensive care medicineGenetic Counseling/ethicsbusiness.industryHematologic Neoplasms/diagnosis/genetics/pathologyCancermedicine.diseasePediatric cancerHuman genetics030104 developmental biologyLi–Fraumeni syndromeNeoplasms/diagnosis/genetics/pathologyMutationMedical/historySocietiesbusinessAmerican journal of medical genetics. Part A
researchProduct